A controversial space mission to test Einstein's general theory of relativity last week was given a reprieve-or enough rope to hang itself. NASA managers have drawn up three tests for the over-budget and behindschedule Gravity Probe-B (GPB) mission and have decreed that failing any one will doom the $600 million project, which is just months from launch.
GPB is in essence a giant and delicate thermos bottle. It is designed to measure a slight rotation of space near the spinning Earth-a phenomenon called frame dragging that is predicted by Einstein's theoryas well as the tiny bending effect of gravity upon light. Technical problems have forced five launch delays in the past 4 years, boosting the mission's cost by $166 million.
In March Ed Weiler, NASA's space science chief, ordered up a technical and scientific review to decide whether to cancel the program in light of the rising costs and continued delays (Science, 21 March, p. 1827) . Its results were presented at a 30 April meeting that included officials from Marshall Space Flight Center in Huntsville, Alabama, and the mission's principal investigator, Stanford University physicist Francis Everitt. Weiler said afterward that he told the GPB team "we will terminate with no further reviews" if the instrument fails either of two thermal vacuum tests or the team fails to come up with a better mission operations plan. Everitt calls the decision "appropriate."
The technical review, chaired by Tom Fraschetti of NASA's Jet Propulsion Laboratory in Pasadena, California, concluded that GPB's hardware is "in fairly good shape" but that technical issues involving a heater, fuses, and a star sensor may require more work. The team was skeptical that the spacecraft will be ready for launch this fall and recommended that it undergo two more thermal cycle tests, which mimic the intense hot and cold of space, following troubles in a similar test late last year. Everitt says that those problems were "blown out of all proportion" and that the test actually was "extremely successful." The team also recommended a more detailed plan for mission operations.
The scientific review, led by University of Chicago physicist Michael Turner, found "some erosion" in the scientific value of the frame-dragging experiment because other missions now in the pipeline should produce results that have a bearing on Einstein's predictions and "more significant erosion" in measuring gravity's effect on light. Everitt says he "vigorously" disagrees with the reviewers, who did not go so far as to claim that GPB is scientifically redundant.
The GPB team is confident that the experiment can be ready for a September launch, although NASA officials think that the end of the year is more likely. And time is money: A November launch adds $10 million to the latest overrun of $20 million to $30 million, and a 6-month delay would cost $30 million to $40 million more.
-ANDREW LAWLER

NASA Orders Make-or-Break Tests for Gravity Probe S PA C E P H Y S I C S
On tenterhooks. NASA says that Gravity Probe-B won't fly if it isn't space-worthy.
CREDITS: (TOP TO BOTTOM) STANFORD UNIVERSITY/GRAVITY PROBE-B; DOUGLAS HEALEY/GETTY IMAGES
WASHINGTON, D.C.-Reality has caught up with the Bush Administration's ambitious plan to vaccinate between 5 million and 10 million Americans against smallpox by this summer. So far, fewer than 35,000 people have received the vaccine, and many states have halted vaccination, awaiting further guidance from the federal government. At a meeting of an Institute of Medicine (IOM) panel last week, several state and local health officials sharply criticized the campaign and urged the government to cancel its second and largest phase, which has begun in only one state, Florida. Officials from the Centers for Disease Control and Prevention (CDC) in Atlanta say what counts is that states and cities are ready to face an attack-not the exact number of vaccinees. But they concede that it is hard to convince people to get the shots. Mustering momentum is likely to be even tougher now that the vaccine has caused unanticipated side effects, the war in Iraq has ended-without turning up any stockpiles of bioweapons so far-and the public health system is preoccupied with SARS.
The Administration spent months deliberating the magnitude of the preparedness campaign, unveiled on 13 December (Science, 20 December 2002 , p. 2312 . Up to 437,000 medical personnel expected to help contain an outbreak would be vaccinated within a month, starting in late January, top Administration officials said at the time, followed by another 5 million to 10 million other medical personnel, law enforcement agents, and firefighters in the next few months. Separately, the Department of Defense revealed a plan to immunize about half a million armed services members. With 422,000 military personnel vaccinated, the latter goal is almost reached, says John Grabenstein, deputy director for military vaccines for the Army's surgeon general. But the civilian program has been beset by resistance from labor unions and a lack of volunteers. One of the foremost objections was solved last week, when Bush signed a law to compensate those hurt by the vaccine. But the program has also suffered from evidence that the vaccine can cause inflammation of the
Smallpox Vaccination Campaign in the Doldrums
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Who's next? Fewer than 35,000 civilians have volunteered for smallpox shots so far. 
